|Bid||326.00 x 800|
|Ask||326.50 x 2200|
|Day's range||317.18 - 335.75|
|52-week range||65.49 - 497.49|
|Beta (5Y monthly)||1.49|
|PE ratio (TTM)||38.58|
|Earnings date||04 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||340.17|
Moderna (NASDAQ: MRNA) is no longer the seemingly invincible, high-flying stock that it once was. There are plenty of reasons why the vaccine stock has lost some of its mojo. To me, there's a much more important question to attempt to answer: How low can Moderna stock actually go?
Moderna (NASDAQ: MRNA) has helped many investors get rich over the past year. The coronavirus vaccine made Moderna profitable after only one full quarter of sales -- and profit topped $1 billion. The coronavirus vaccine giant predicts $20 billion in vaccine sales this year.
Former U.S. Commerce Sec. Gary Locke weighs in on the global vaccine equity debate and how the U.S. can better respond to the ongoing pandemic.